BioAdaptives Files 8-K: Regulation FD Disclosure
Ticker: BDPT · Form: 8-K · Filed: Nov 27, 2024 · CIK: 1575142
| Field | Detail |
|---|---|
| Company | Bioadaptives, INC. (BDPT) |
| Form Type | 8-K |
| Filed Date | Nov 27, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
TL;DR
BioAdaptives filed an 8-K on Nov 26th, mostly procedural stuff, check for details.
AI Summary
BioAdaptives, Inc. filed an 8-K on November 27, 2024, reporting events as of November 26, 2024. The filing is primarily a Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided text.
Why It Matters
This filing indicates BioAdaptives, Inc. is providing required disclosures to the SEC, which may contain updates relevant to investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial data that would indicate a high risk.
Key Players & Entities
- BIOADAPTIVES, INC. (company) — Registrant
- November 26, 2024 (date) — Date of earliest event reported
- November 27, 2024 (date) — Filing Date
- 2620 Regatta Drive, Suite 102, Las Vegas, Nevada 89128 (address) — Principal Executive Office
FAQ
What is the primary purpose of this 8-K filing for BioAdaptives, Inc.?
The filing serves as a Regulation FD Disclosure and includes Financial Statements and Exhibits, as reported on November 27, 2024, for events as of November 26, 2024.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is BIOADAPTIVES, INC.
In which state was BioAdaptives, Inc. incorporated?
BioAdaptives, Inc. was incorporated in Delaware.
What is the business address of BioAdaptives, Inc.?
The business address is 2620 Regatta Drive, Suite 102, Las Vegas, Nevada 89128.
What is the telephone number for BioAdaptives, Inc.?
The telephone number is (702) 659-8829.
Filing Stats: 388 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-11-26 18:00:09
Filing Documents
- bdpt_8k.htm (8-K) — 20KB
- bdpt_ex991.htm (EX-99.1) — 5KB
- bdpt_8kimg5.jpg (GRAPHIC) — 5KB
- 0001640334-24-001796.txt ( ) — 153KB
- bdpt-20241126.xsd (EX-101.SCH) — 6KB
- bdpt-20241126_lab.xml (EX-101.LAB) — 13KB
- bdpt-20241126_cal.xml (EX-101.CAL) — 1KB
- bdpt-20241126_pre.xml (EX-101.PRE) — 8KB
- bdpt-20241126_def.xml (EX-101.DEF) — 2KB
- bdpt_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The Company issued press release on November 25, 2024, announcing the approval of a human clinical trial for its product, Zeranovia, by an Institutional Review Board. Copies of these press releases are furnished as Exhibits 99.1 and 99.1(1) to this Current Report on Form 8-K. The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release (11/25/24) 2 SIGNATURE Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioAdaptives, Inc. November 26, 2024 /s/ James E Keener James E Keener CEO 3